Eli Lilly and Company (NYSE:LLY) Shares Sold by Timber Creek Capital Management LLC

Timber Creek Capital Management LLC cut its stake in Eli Lilly and Company (NYSE:LLY) by 0.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,546 shares of the company’s stock after selling 12 shares during the period. Eli Lilly and Company accounts for approximately 3.4% of Timber Creek Capital Management LLC’s investment portfolio, making the stock its 7th largest holding. Timber Creek Capital Management LLC’s holdings in Eli Lilly and Company were worth $11,359,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Everpar Advisors LLC bought a new stake in Eli Lilly and Company during the 4th quarter valued at $1,845,000. International Assets Investment Management LLC raised its stake in shares of Eli Lilly and Company by 5.3% during the fourth quarter. International Assets Investment Management LLC now owns 12,597 shares of the company’s stock valued at $7,343,000 after purchasing an additional 632 shares in the last quarter. Tennessee Valley Asset Management Partners acquired a new stake in Eli Lilly and Company in the fourth quarter worth about $181,000. SVB Wealth LLC grew its position in Eli Lilly and Company by 2.3% in the 4th quarter. SVB Wealth LLC now owns 16,304 shares of the company’s stock valued at $9,504,000 after buying an additional 362 shares in the last quarter. Finally, Octavia Wealth Advisors LLC grew its position in Eli Lilly and Company by 43.6% in the 4th quarter. Octavia Wealth Advisors LLC now owns 734 shares of the company’s stock valued at $428,000 after buying an additional 223 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Truist Financial reaffirmed a “buy” rating and set a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, August 5th. JPMorgan Chase & Co. upped their price objective on Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. Finally, Guggenheim raised their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday. Two research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $956.88.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the transaction, the executive vice president now owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The disclosure for this sale can be found here. Insiders sold a total of 1,214,704 shares of company stock worth $1,066,841,316 in the last quarter. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Down 1.0 %

NYSE LLY traded down $9.46 during trading on Friday, reaching $922.12. 2,364,894 shares of the company’s stock were exchanged, compared to its average volume of 3,096,824. The firm has a market capitalization of $876.39 billion, a PE ratio of 135.74, a P/E/G ratio of 1.81 and a beta of 0.41. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $966.10. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The company’s fifty day simple moving average is $878.93 and its 200-day simple moving average is $804.05.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s payout ratio is presently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.